Sylvie Ryckebusch - BioInvent International Chief Officer
| BINV Stock | SEK 27.80 2.40 9.45% |
Insider
Sylvie Ryckebusch is Chief Officer of BioInvent International AB
| Phone | 46 4 62 86 85 50 |
| Web | https://www.bioinvent.com |
BioInvent International Management Efficiency
The company has return on total asset (ROA) of (0.0192) % which means that it has lost $0.0192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0274) %, meaning that it generated substantial loss on money invested by shareholders. BioInvent International's management efficiency ratios could be used to measure how well BioInvent International manages its routine affairs as well as how well it operates its assets and liabilities.BioInvent International AB has accumulated 21.53 M in total debt with debt to equity ratio (D/E) of 22.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioInvent International has a current ratio of 2.68, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist BioInvent International until it has trouble settling it off, either with new capital or with free cash flow. So, BioInvent International's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioInvent International sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioInvent to invest in growth at high rates of return. When we think about BioInvent International's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Emanuel Bjrne | Hansa Biopharma AB | 50 | |
| Nina Valkama | Cantargia AB | N/A | |
| Ignacio GarciaRibas | Cantargia AB | N/A | |
| Johanna Christensen | Cantargia AB | N/A | |
| Palle MS | Saniona AB | 65 | |
| Susanne Lagerlund | Cantargia AB | N/A | |
| Sren MSc | Hansa Biopharma AB | 58 | |
| Dominique Tersago | Cantargia AB | 61 | |
| Jakob Lic | Oncopeptides AB | 51 | |
| Annika MBA | Oncopeptides AB | 57 | |
| Jorgen Drejer | Saniona AB | 68 | |
| Peter Madsen | Cantargia AB | N/A | |
| Marcuss | Cantargia AB | N/A | |
| Janus Larsen | Saniona AB | 51 | |
| Thoas MD | Cantargia AB | 61 | |
| Linda Holmstrom | Oncopeptides AB | N/A | |
| MSc MSc | Oncopeptides AB | 53 | |
| Klaus Sindahl | Hansa Biopharma AB | N/A | |
| Peter Nygren | Oncopeptides AB | 64 | |
| Katja Margell | Hansa Biopharma AB | N/A | |
| Anita BCom | Saniona AB | 55 | |
Management Performance
| Return On Equity | -0.0274 | |||
| Return On Asset | -0.0192 |
BioInvent International Leadership Team
Elected by the shareholders, the BioInvent International's board of directors comprises two types of representatives: BioInvent International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioInvent. The board's role is to monitor BioInvent International's management team and ensure that shareholders' interests are well served. BioInvent International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioInvent International's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Martin Welschof, President CEO | ||
| Andres McAllister, Chief Medical Officer | ||
| Stefan MBA, Chief Officer | ||
| Ingrid Teige, Head Research | ||
| RGN MSc, Chief Officer | ||
| Cecilia Hofvander, Director Relations | ||
| Kristoffer Hansson, Vice President Technical Operations | ||
| Sylvie Ryckebusch, Chief Officer | ||
| Bjrn Frendus, Chief Officer |
BioInvent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioInvent International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0274 | |||
| Return On Asset | -0.0192 | |||
| Profit Margin | (0.14) % | |||
| Operating Margin | (0.16) % | |||
| Current Valuation | 1.16 B | |||
| Shares Outstanding | 65.8 M | |||
| Shares Owned By Insiders | 11.10 % | |||
| Shares Owned By Institutions | 57.02 % | |||
| Price To Earning | (9.49) X | |||
| Price To Book | 1.40 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for BioInvent Stock Analysis
When running BioInvent International's price analysis, check to measure BioInvent International's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioInvent International is operating at the current time. Most of BioInvent International's value examination focuses on studying past and present price action to predict the probability of BioInvent International's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioInvent International's price. Additionally, you may evaluate how the addition of BioInvent International to your portfolios can decrease your overall portfolio volatility.